Listing 1 - 3 of 3 |
Sort by
|
Choose an application
This Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision support, and the incorporation of PGx into clinical care.
Medicine --- Pharmacology --- pharmacogenomics --- return of results --- genetic counseling --- qualitative --- pharmacogenetics --- implementation --- pharmacogenetics service --- screening --- pre-emptive --- personalized medicine --- precision medicine --- community pharmacy --- pharmacogenomic testing --- genetic privacy --- pharmaco-economics --- polymorphisms --- pharmacogenes --- pharmacogenomic --- machine learning --- adaptation --- human evolution --- US Food and Drug Administration --- clinical actionability --- clinical translation --- chronic kidney disease --- CYP3A5 --- polymorphism --- progression --- pharmacogenomics (PGx) --- pediatrics --- best practice alerts (BPAs) --- electronic health records (EHR) --- genomic indicators --- clinical decision support (CDS) --- phenotype --- genotype --- polypharmacy --- chronic disease --- medication management --- electronic medical record --- artificial intelligence --- n/a
Choose an application
This Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision support, and the incorporation of PGx into clinical care.
pharmacogenomics --- return of results --- genetic counseling --- qualitative --- pharmacogenetics --- implementation --- pharmacogenetics service --- screening --- pre-emptive --- personalized medicine --- precision medicine --- community pharmacy --- pharmacogenomic testing --- genetic privacy --- pharmaco-economics --- polymorphisms --- pharmacogenes --- pharmacogenomic --- machine learning --- adaptation --- human evolution --- US Food and Drug Administration --- clinical actionability --- clinical translation --- chronic kidney disease --- CYP3A5 --- polymorphism --- progression --- pharmacogenomics (PGx) --- pediatrics --- best practice alerts (BPAs) --- electronic health records (EHR) --- genomic indicators --- clinical decision support (CDS) --- phenotype --- genotype --- polypharmacy --- chronic disease --- medication management --- electronic medical record --- artificial intelligence --- n/a
Choose an application
This Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision support, and the incorporation of PGx into clinical care.
Medicine --- Pharmacology --- pharmacogenomics --- return of results --- genetic counseling --- qualitative --- pharmacogenetics --- implementation --- pharmacogenetics service --- screening --- pre-emptive --- personalized medicine --- precision medicine --- community pharmacy --- pharmacogenomic testing --- genetic privacy --- pharmaco-economics --- polymorphisms --- pharmacogenes --- pharmacogenomic --- machine learning --- adaptation --- human evolution --- US Food and Drug Administration --- clinical actionability --- clinical translation --- chronic kidney disease --- CYP3A5 --- polymorphism --- progression --- pharmacogenomics (PGx) --- pediatrics --- best practice alerts (BPAs) --- electronic health records (EHR) --- genomic indicators --- clinical decision support (CDS) --- phenotype --- genotype --- polypharmacy --- chronic disease --- medication management --- electronic medical record --- artificial intelligence
Listing 1 - 3 of 3 |
Sort by
|